| 0.4731 -0.016 (-3.27%) | 12-08 13:18 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.59 | 1-year : | 0.69 |
| Resists | First : | 0.51 | Second : | 0.59 |
| Pivot price | 0.45 |
|||
| Supports | First : | 0.37 | Second : | 0.3 |
| MAs | MA(5) : | 0.46 |
MA(20) : | 0.44 |
| MA(100) : | 0.68  |
MA(250) : | 0.97 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 75.7 |
D(3) : | 77.6 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 2.14 | Low : | 0.37 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ QLI ] has closed below upper band by 31.9%. Bollinger Bands are 38.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.5 - 0.5 | 0.5 - 0.51 |
| Low: | 0.43 - 0.44 | 0.44 - 0.44 |
| Close: | 0.47 - 0.47 | 0.47 - 0.48 |
Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.
Fri, 09 Jul 2021
Qilian International Holding Group Limited Enters into Investment Agreement for Pig By-product Processing Project in ... - GlobeNewswire
Wed, 13 Jan 2021
NASDAQ:QLI - Qilian International Holding Group Stock Price, News & Analysis - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—Specialty & Generic
|
|
| Shares Out | 36 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 77.4 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 13 (K) |
| Shares Short P.Month | 13 (K) |
| EPS | 0.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.48 |
| Profit Margin | 2.4 % |
| Operating Margin | 0.7 % |
| Return on Assets (ttm) | 0.9 % |
| Return on Equity (ttm) | 2.7 % |
| Qtrly Rev. Growth | -9.2 % |
| Gross Profit (p.s.) | 0.17 |
| Sales Per Share | 1.73 |
| EBITDA (p.s.) | 0.05 |
| Qtrly Earnings Growth | 464.2 % |
| Operating Cash Flow | 8 (M) |
| Levered Free Cash Flow | 12 (M) |
| PE Ratio | 11.82 |
| PEG Ratio | 0 |
| Price to Book value | 0.31 |
| Price to Sales | 0.27 |
| Price to Cash Flow | 2.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|